A-Alpha Bio
AI Healthcare
drug discovery and protein engineering
Series A2
A-Alpha Bio is a Seattle-based biotechnology platform company that uses synthetic biology, machine learning, and protein engineering to measure, predict, and engineer protein-protein interactions for drug discovery and therapeutic development. Its platforms include AlphaSeq for large-scale interaction measurement and AlphaBind for sequence-based binding prediction, and it works with pharmaceutical and biotechnology partners to generate data and optimize biologics and other protein therapeutics.
Company Details
- Website
- aalphabio.com
- Headquarters
- Seattle, Washington, United States
- Founded
- 2017
- Funding
- $51M (at least; some sources indicate $65.1M including later grants, but the latest clearly stated e
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring